About the Project
This project aims at developing innovative bioactive formulations for advanced micro 3D bioprinting. The student will design new bioink formulations based on the proprietary CLEX technology. The formulations will be evaluated and adapted using state-of-the-art 3D bioprinting methods and selected 3D cell culture models. Ultimately, the developed bioinks and printing processes will be demonstrated in a microstructured multi-component 3D tissue unit.
The project builds on the results of over 7 years of R&D at the University of Birmingham, Harvard University, EPFL, and NTNU. ClexBio envisions a world where no patient needs to die while waiting for an organ transplant, and where organ models can help predict the effect of pharmaceuticals more accurately such that they can get in the hands of suffering patients faster. The technological foundation of ClexBio is the proprietary hydrogel technology CLEX, which was designed to overcome key challenges in biofabrication and deposit living cells in close proximity on the micro-scale. Combining advanced biofabrication tools, biomaterials, and primary human cells, ClexBio engineers living human tissues for preclinical and clinical applications.
To be eligible for EPSRC funding candidates must have at least a 2(1) in an Engineering or Scientific discipline or a 2(2) plus MSc. Please email your c.v. to firstname.lastname@example.org. For details on the Engineering Doctorate scheme visit the homepage. Deadline 30 April 2021
Why not add a message here
Based on your current searches we recommend the following search filters.
Based on your current search criteria we thought you might be interested in these.